Gene · 5205
Papers1,828
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 1,828
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multi-omics integration analysis unveils heterogeneity in breast cancer at the individual level. | Cell Cycle | 2023 | 37974462 | PubTator, text mining | PubMed |
| A state-of-the-art review on the NRF2 in Hepatitis virus-associated liver cancer. | Cell Commun Signal | 2023 | 37946175 | PubTator, text mining | PubMed |
| Vitamin B5 supports MYC oncogenic metabolism and tumor progression in breast cancer. | Nat Metab | 2023 | 37946084 | PubTator, text mining | PubMed |
| MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis. | Nat Cell Biol | 2023 | 37945904 | PubTator, text mining | PubMed |
| TCR Pathway Mutations in Mature T Cell Lymphomas. | J Immunol | 2023 | 37931208 | PubTator, text mining | PubMed |
| PGP-14 establishes a polar lipid permeability barrier within the C. elegans pharyngeal cuticle. | PLoS Genet | 2023 | 37930961 | PubTator, text mining | PubMed |
| Downregulation of complement factor H attenuates the stemness of MDA‑MB‑231 breast cancer cells via modulation of the ERK and p38 signaling pathways. | Oncol Lett | 2023 | 37927420 | PubTator, text mining | PubMed |
| High Expression of NRF2 and Low Expression of KEAP1 Predict Worse Survival in Patients With Operable Triple-Negative Breast Cancer. | J Breast Cancer | 2023 | 37926068 | PubTator, text mining | PubMed |
| Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR. | J Exp Clin Cancer Res | 2023 | 37924112 | PubTator, text mining | PubMed |
| Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival. | Sci Rep | 2023 | 37923775 | PubTator, text mining | PubMed |
| Classification of HER2-negative breast cancers by ERBB2 copy number alteration status reveals molecular differences associated with chromosome 17 gene aberrations. | Ther Adv Med Oncol | 2023 | 37920257 | PubTator, text mining | PubMed |
| Proteomic analyses of smear-positive/negative tuberculosis patients uncover differential antigen-presenting cell activation and lipid metabolism. | Front Cell Infect Microbiol | 2023 | 37908762 | PubTator, text mining | PubMed |
| Sarcopenia is associated with osteopenia and impaired quality of life in children with genetic intrahepatic cholestatic liver disease. | Hepatol Commun | 2023 | 37902507 | PubTator, text mining | PubMed |
| Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer Using Nine-Gene Expression Signature. | World J Oncol | 2023 | 37869243 | PubTator, text mining | PubMed |
| Metabolic stratification of human breast tumors reveal subtypes of clinical and therapeutic relevance. | iScience | 2023 | 37854701 | PubTator, text mining | PubMed |
| Trimodal single-cell profiling reveals a novel pediatric CD8αα+ T cell subset and broad age-related molecular reprogramming across the T cell compartment. | Nat Immunol | 2023 | 37845489 | PubTator, text mining | PubMed |
| Integration of bioinformatics and machine learning strategies identifies APM-related gene signatures to predict clinical outcomes and therapeutic responses for breast cancer patients. | Neoplasia | 2023 | 37839160 | PubTator, text mining | PubMed |
| Investigation of LGALS2 expression in the TCGA database reveals its clinical relevance in breast cancer immunotherapy and drug resistance. | Sci Rep | 2023 | 37838802 | PubTator, text mining | PubMed |
| Development of Engineered-U1 snRNA Therapies: Current Status. | Int J Mol Sci | 2023 | 37834063 | PubTator, text mining | PubMed |
| Recurrent early-onset severe obstetric cholestasis in a patient with two variants in the ABCB4 gene. | Hepatol Forum | 2023 | 37822304 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5205/papers?page=8